Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer.

CPT: pharmacometrics & systems pharmacology - 1 Aug 2021

Sayama Hiroyuki, Marcantonio Diana, Nagashima Takeyuki, Shimazaki Masashi, Minematsu Tsuyoshi, Apgar Joshua F, Burke John M, Wille Lucia, Nagasaka Yasuhisa, Kirouac Daniel C

Abstract excerpt

KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and selective inhibitor of KRASG12C . Although preclinical data suggested impressive efficacy, it remains unclear whether ASP2453 will show more favorable clinical response compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Organic Chemicals

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34043291
DOI: 10.1002/psp4.12661
PMCID: PMC8376128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer.PMID 34043291Read ↗

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.Semantic proximity Read ↗

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

A quantitative systems pharmacology analysis of KRAS G12C covalent inhibitorsSemantic proximity Read ↗

Structure-Based Virtual Screening for Novel Inhibitors Targeting KRAS G12C.Semantic proximity Read ↗

CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.Semantic proximity Read ↗

MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCERSemantic proximity Read ↗

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors.Semantic proximity Read ↗

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational modelSemantic proximity Read ↗

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cellsSemantic proximity Read ↗

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.